Mirxes Holding Co Ltd
02629
Company Profile
Business description
Mirxes Holding Co Ltd is a miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, including Singapore and China. It has one Core Product (namely, GASTROClearTM), two other commercialized products (namely, LUNGClearTM and FortitudeTM), and six product candidates at the pre-clinical stage, as illustrated in the chart below. GASTROClearTM, its Core Product, is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. The company generates the majority of its revenue from Singapore.
Contact
2 Tukang Innovation Grove
No. 09-02 JTC MedTech Hub
Singapore618305
SGPT: +65 68162931
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
347
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,409.41 | 72.12 | 0.87% |
| DAX 40 | 25,283.99 | 243.71 | 0.97% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,526.04 | 47.70 | 0.46% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |